Platinum Resistant Primary Peritoneal Cancer
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB12489 | Mirvetuximab soravtansine | A folate receptor alpha-directed antibody and microtubule inhibitor conjugate used to treat folate receptor alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB12489 | Mirvetuximab soravtansine | Cytochrome P450 3A4 | enzyme |
| DB12489 | Mirvetuximab soravtansine | Folate receptor alpha | target |
| DB12489 | Mirvetuximab soravtansine | P-glycoprotein 1 | transporter |
| Drug | Drug Name | Phase | Status | Count |
|---|